Forget Centessa Pharmaceuticals: This Rare-Disease Specialist Has a Superior Portfolio and Pipeline [Yahoo! Finance]
Centessa Pharmaceuticals (CNTA) was upgraded by Wolfe Research to "strong-buy".
Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $40.00 price target on the stock.
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Truist Financial Corporation from $33.00 to $38.00. They now have a "buy" rating on the stock.